Yongjun Xue

515 total citations
37 papers, 354 citations indexed

About

Yongjun Xue is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Yongjun Xue has authored 37 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Hematology and 7 papers in Oncology. Recurrent topics in Yongjun Xue's work include Multiple Myeloma Research and Treatments (8 papers), Drug Transport and Resistance Mechanisms (7 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Yongjun Xue is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Drug Transport and Resistance Mechanisms (7 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Yongjun Xue collaborates with scholars based in United States, Germany and Sweden. Yongjun Xue's co-authors include Edward S. Yeung, F. Kutlar, Maria Palmisano, Marlene Wade, Paul Swerdlow, Laura G. Corral, Abdullah Kutlar, Steffen E. Meiler, Laure A Moutouh-de Parseval and Liangang Liu and has published in prestigious journals such as Blood, Analytical Chemistry and The Science of The Total Environment.

In The Last Decade

Yongjun Xue

31 papers receiving 337 citations

Peers

Yongjun Xue
Takehiko Kawanishi Japan
Kamila Balušíková Czechia
Carola W.N. Damen Netherlands
M.J. Bossard United States
Ronghua Meng China
Andrew Lasslo United States
Sridhar Veeraraghavan India
Natalie M. G. M. Appels Netherlands
V. Monzani Italy
Wenya Feng China
Takehiko Kawanishi Japan
Yongjun Xue
Citations per year, relative to Yongjun Xue Yongjun Xue (= 1×) peers Takehiko Kawanishi

Countries citing papers authored by Yongjun Xue

Since Specialization
Citations

This map shows the geographic impact of Yongjun Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongjun Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongjun Xue more than expected).

Fields of papers citing papers by Yongjun Xue

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongjun Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongjun Xue. The network helps show where Yongjun Xue may publish in the future.

Co-authorship network of co-authors of Yongjun Xue

This figure shows the co-authorship network connecting the top 25 collaborators of Yongjun Xue. A scholar is included among the top collaborators of Yongjun Xue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongjun Xue. Yongjun Xue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yee, Sook Wah, Jia Yang, Claire M. Brett, et al.. (2025). Identification and Clinical Evaluation of Potential Biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2). Clinical Pharmacology & Therapeutics. 118(1). 177–189. 1 indexed citations
2.
Chen, Ping, Hongxia Lin, Yongjun Xue, et al.. (2025). A population pharmacokinetic analysis to evaluate the impact of renal impairment on the pharmacokinetics of iberdomide. Journal of Pharmaceutical Sciences. 114(2). 1315–1325.
3.
4.
Nishii, Rina, Yongjun Xue, Runlan Huo, et al.. (2025). Evaluating the utility of endogenous OCT2 and MATE1/2-K biomarkers for DDI assessment in early clinical settings. Journal of Pharmaceutical Sciences. 114(12). 103776–103776.
5.
Xue, Yongjun, Chenyu Jiang, Dagang Liu, et al.. (2024). 3-Dimentional printing of polysaccharides for water-treatment: A review. International Journal of Biological Macromolecules. 265(Pt 2). 131117–131117. 7 indexed citations
6.
Huo, Runlan, Yueping Zhang, Weiqi Chen, et al.. (2024). A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants. Journal of Pharmacology and Experimental Therapeutics. 390(2). 162–173. 11 indexed citations
7.
Xue, Yongjun, Runlan Huo, Mu Chen, et al.. (2024). 1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug–Drug Interaction Potential. Drug Metabolism and Disposition. 52(9). 966–974. 3 indexed citations
8.
Cheng, Yiming, Allison Gaudy, Liangang Liu, et al.. (2023). Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide. Clinical Pharmacology in Drug Development. 12(8). 819–825. 1 indexed citations
9.
Chen, Yizhe, D.J. Wyatt, Massimo Attanasio, et al.. (2023). Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults. Cancer Chemotherapy and Pharmacology. 93(4). 307–317. 2 indexed citations
10.
11.
Chu, Jessica, Anthony M. Marino, Xueqing Chen, et al.. (2023). Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions. Pharmaceutical Research. 40(11). 2567–2584. 3 indexed citations
12.
Wang, Yongjie, Li Chen, Yuanyuan Chen, et al.. (2023). Effects of varying amounts of different biochars on mercury methylation in paddy soils and methylmercury accumulation in rice (Oryza sativa L.). The Science of The Total Environment. 874. 162459–162459. 9 indexed citations
13.
Zhang, Yueping, Petia Shipkova, Bethanne M. Warrack, et al.. (2023). Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein–Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo. Drug Metabolism and Disposition. 51(7). 851–861. 11 indexed citations
14.
OGASAWARA, K., Mark Thomas, Liangang Liu, et al.. (2021). Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. Cancer Chemotherapy and Pharmacology. 88(3). 369–377. 8 indexed citations
15.
OGASAWARA, K., Mark Thomas, Michael A. Thomas, et al.. (2021). Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach. Cancer Chemotherapy and Pharmacology. 88(6). 941–952. 13 indexed citations
16.
Keller, Stephen, Jorge Quiroz, Enaksha Wickremsinhe, et al.. (2021). The Effectiveness of Quality Control Samples in Pharmaceutical Bioanalysis. Bioanalysis. 13(3). 135–145.
17.
Chen, Jian, et al.. (2016). WRIB Poster Award Winners. Bioanalysis. 8(17). 1761–1764.
18.
Meiler, Steffen E., Marlene Wade, F. Kutlar, et al.. (2011). Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood. 118(4). 1109–1112. 61 indexed citations
19.
Zhang, Donglu, Nirmala Raghavan, Lifei Wang, et al.. (2010). Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment. Drug Metabolism and Disposition. 39(1). 123–131. 22 indexed citations
20.
Wang, Lifei, Donglu Zhang, Arun Swaminathan, et al.. (2005). GLUCURONIDATION AS A MAJOR METABOLIC CLEARANCE PATHWAY OF 14C-LABELED MURAGLITAZAR IN HUMANS: METABOLIC PROFILES IN SUBJECTS WITH OR WITHOUT BILE COLLECTION. Drug Metabolism and Disposition. 34(3). 427–439. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takehiko Kawanishi Breakdown of academic impact, for papers by Kamila Balušíková Breakdown of academic impact, for papers by Carola W.N. Damen Breakdown of academic impact, for papers by M.J. Bossard Breakdown of academic impact, for papers by Ronghua Meng Breakdown of academic impact, for papers by Andrew Lasslo Breakdown of academic impact, for papers by Sridhar Veeraraghavan Breakdown of academic impact, for papers by Natalie M. G. M. Appels Breakdown of academic impact, for papers by V. Monzani Breakdown of academic impact, for papers by Wenya Feng
Rankless by CCL
2026